Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2016-01-07 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
西南证券股份有限公司关于公司限售股解禁的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion regarding the lifting of restrictions on the circulation of restricted shares of a company (普洛药业股份有限公司). It includes extensive information about the company's major asset restructuring, share issuance, capital changes, shareholder commitments, and shareholding structure changes. The document is not a full annual or interim report, nor is it a simple announcement. It is a specialized verification opinion related to share circulation and compliance with regulatory requirements. This type of document is typically classified as a Regulatory Filing (RNS) because it does not fit into other specific categories like capital updates (CAP) or share issue announcements (SHA) directly, and it is not a report publication announcement (RPA) since it contains substantive content rather than just a notice. The document length is under 5,000 characters, but it contains detailed verification content rather than just a brief announcement, supporting the RNS classification.
2016-01-07 Chinese
限售股上市流通的提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement from 普洛药业股份有限公司 regarding the lifting of restrictions on certain shares, allowing them to be freely traded starting January 11, 2016. It details the number of shares becoming tradable, the shareholders involved, the shareholding structure before and after the lifting of restrictions, and compliance with relevant laws and regulations. The document does not contain financial statements or detailed financial analysis but serves as an official notice about changes in share liquidity and shareholder rights. This fits the definition of a Share Issue/Capital Change announcement, as it relates to changes in share status and capital structure, specifically the release of restricted shares for trading.
2016-01-07 Chinese
关于控股子公司撤回药品注册申请的提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1429 characters) from a company about its controlling subsidiary withdrawing drug registration applications. It references a regulatory announcement from the National Medical Products Administration and details about the withdrawn drug applications. There is no financial data, no report attached or published, and no mention of a meeting or voting results. The document is an official company announcement about regulatory compliance and operational updates related to drug registration, not a financial report or management report. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2015-12-24 Chinese
关于对外投资在香港设立公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's external investment to establish a subsidiary in Hong Kong. It details the investment amount, the investment path, the new company's basic information, and the expected impact on the company. There is no financial data, no mention of a report being attached or published, and no regulatory certification or voting results. The content is about a capital investment activity, specifically the establishment of a new company using the company's own funds. This fits the category of Capital/Financing Update (CAP). The document length is short and focused on the investment announcement, not a full financial report or other categories.
2015-12-14 Chinese
关于公司独立董事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of an independent director from the company's board. It discusses the impact on board composition and compliance with regulatory requirements for independent directors. There is no financial data, no mention of financial results, no report attached or referenced, and no indication of a meeting or voting results. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2015-12-11 Chinese
关于实施2014年度利润分配方案后调整非公开发行股票发行价格和发行数量的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the adjustment of the non-public issuance price and quantity of shares following the implementation of the 2014 profit distribution plan. It details changes in issuance price and share numbers due to dividend distribution and capital changes. The document is relatively short (2127 characters) and focuses on capital raising activities and share issuance adjustments. It is not a full financial report, earnings release, or management discussion. It is clearly an update on financing activities related to share issuance. Therefore, the document fits best under Capital/Financing Update (CAP).
2015-12-10 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.